Development of a New Hybrid Biodegradable Drug-Eluting Stent for the Treatment of Peripheral Artery Disease

Table 1

Quantitative imaging analyses.

	Group 1; ()	Group 2; ()	Group 3; ()	Group 4; ()
Preprocedure RD (mm)					0.453
4-week follow-up
RD (mm)					0.778
MLD (mm)					0.013
DS (%)					0.032
8-week follow-up
RD (mm)					0.242
MLD (mm)					0.108
DS (%)					0.172

Group 1: bare-metal stent (BMS), group 2: drug-free hybrid stent, group 3: 50% PTX/PLGA (fast PTX-releasing form) hybrid stent, and group 4: 30% PTX/PLGA (slow PTX-releasing form) hybrid stent.
RD: reference diameter, MLD: minimal luminal diameter, and DS: diameter stenosis.